|
|
 |
| Indirect CD34 MicroBead Kit |
|
| Overview |
The Indirect CD34 MicroBead Kit was developed for the isolation of CD34+ precursor cells, using a two-step procedure involving indirect magnetic labeling from
- peripheral blood
- bone marrow
- leukapheresis product
- cord blood
- differentiated-ES and iPS cells
Even faster, one-step isolation of CD34+ cells can be achieved with the CD34 MicroBead Kit. |
| Details |
Background information
CD34 is a well-established marker of human hematopoietic stem and progenitor cells and additionally expressed on hemangioblasts1,2, endothelial progenitor cells1,3-5, and mature endothelial cells4.
Detailed separation procedure
First, cells are labeled with the hapten-modified CD34 primary antibody QBEND/106. In a second step, antibody-labeled cells are magnetically labeled with Anti-Hapten MicroBeads.
Control staining of cells isolated with the Indirect CD34 MicroBead Kit requires a monoclonal CD34 antibody other than QBEND/10, e.g. clone AC136
Downstream applications
- Transplantation of CD34+ cells into humanized mouse models
- Expansion and differentiation in culture
- Reprogramming of CD34+ HSCs into iPS cells
- Differentiation of ES or iPS cell-derived CD34+ -derived precursors into endothelial or hematopoietic lineages
- Evaluation of differentiation potential in CFU assays
- Characterization of surface marker expression by flow cytometry.
|
| Clone | Isotype |
| QBEND/10 | Mouse IgG1 |
| |
| Figure 1 |
| May-Grünwald-Giemsa–stained CD34+ cells isolated from bone marrow aspirate using the Indirect CD34 MicroBead Kit, an MS Column and a MiniMACS™ Separator. |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| Indirect CD34 MicroBead Kit, human |
- for 2×109 total cells
Components
- 2 mL CD34-Hapten-Antibody
- 2 mL Anti-Hapten MicroBeads
- 2 mL FcR Blocking Reagent
Download datasheet
130-046-701
|
|
| References |
| 1. Wang et al. (2007) Nat. Biotechnol. 25: 317–318. |
| 2. Loges et al. (2004) Stem Cells Dev. 13: 229–242. |
| 3. Peichev et al. (2000) Blood 95: 952–958. |
| 4. Rafii and Lyden (2003) Nat. Med. 9: 702–712. |
| 5. Valgimigli et al. (2004) Circulation 110:1209–1212. |
| 6. Lanza et al. (2001) J. Biol. Regul. Homeost. Agents 15: 1–13. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
